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Delirium is common in the last weeks or days of life.1 It can be
distressing for patients and those around them. Successful
management involves excluding reversible causes of delirium
and balancing drugs that may provoke or maintain delirium
while appreciating that most patients want to retain clear
cognition at the end of life.
What is delirium?
Delirium is the abrupt onset of fluctuating confusion, inattention,
and reduced awareness of the environment. Symptoms can affect
different areas of cognition (memory, orientation, language,
visuospatial ability, or perception) and may include
hallucinations and disturbances in the sleep-wake cycle (box
1).2 Delirium can therefore be distressing to people who
experience it and those around them.3Delirium is classified into
hyperactive (restlessness and agitated behaviour predominate),
hypoactive (drowsiness and inactivity predominate), and mixed
subtypes. The more subtle changes associated with the
hypoactive form are often missed.4
What are the causes of delirium?
Delirium occurs when physical factors, often occurring
simultaneously (box 2), act on a physiologically vulnerable
brain, leading to confusion, changes in perceptions, and altered
behaviours.6 In the last days of life, delirium has been described
as the visible culmination of end stage multiorgan failure
compounded by other non-reversible factors.7
In an observational study of 213 terminally ill delirious patients
with cancer,8 the main causes identified were hepatic failure,
drugs, pre-renal azotemia, hyperosmolality, hypoxia,
disseminated intravascular coagulation, organic damage to the
central nervous system, infection, and hypercalcaemia. In the
same study, the occurrence of hyperactive delirium and the
requirement for sedation correlated with hepatic failure, opioids,
and steroids, while dehydration related conditions were
statistically significantly associated with hypoactive delirium.
Who gets delirium at the end of life?
A systematic review suggested that 13-42% of patients admitted
to palliative care inpatient units have delirium.9 A cohort study
of patients with advanced cancer on a palliative care inpatient
unit estimated that this rose to 88% in the days and hours before
death.1
Pre-existing cognitive impairment, increased age, an already
severe illness state, and infection reduce the brain’s ability to
resist delirium.10 Smaller observational studies in cancer patients
found that lower performance status, the presence of lung cancer,
and shorter time since diagnosis were associated with developing
cognitive impairment.11A retrospective study in cancer patients
reported that male sex and the presence of a primary or
metastatic brain tumour predisposed to delirium.12
Poor prognostic factors for delirium, predictive of non-recovery
from the episode, include severe delirium, irreversible
precipitating factors, greater degree of cognitive impairment,
the hypoactive subtype, and a previous episode of delirium.
Delirium caused by hypoxic or metabolic encephalopathy is
particularly resistant to reversal,7whereas delirium precipitated
by drugs, electrolyte abnormalities, and infection are more likely
to be reversible.8 13
How to identify delirium at the end of life
The core clinical features of delirium are the rapid onset of
disturbed attention, fluctuating levels of consciousness, cognitive
impairment, psychomotor disturbance, and disruption of the
sleep-wake cycle. In our experience, within palliative care these
core features often show as purposeless repetitive movements,
such as plucking at bed sheets and removing clothes,
accompanied by moaning and facial grimacing. Emotional
changes, such as fear, anxiety, and agitation are common.
Multifocal myoclonus, which may reflect opioid toxicity, renal
failure, or other drug related toxicity, may be seen.14
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What you need to know
• Consider delirium in any patient in palliative care who shows a change in behaviour
• Investigate underlying causes where appropriate in line with the patient’s pre-expressed wishes
• Optimise the patient’s environment and review drugs
• Consider low dose haloperidol first line in people with delirium who are distressed or considered a risk to themselves or others, and
in whom conservative management is ineffective or inappropriate
• Additional sedation with lorazepam or midazolam may be appropriate if delirium is irreversible and haloperidol alone does not reduce
the distress and risks
Sources and selection criteria
We searched Medline, Clinical Evidence, and the Cochrane Library using the terms delirium, terminal, terminal care, palliative care, palliative
medicine, and end of life. Where possible we used systematic reviews and referenced these rather than the individual trials. Our search
was limited to citations from 1990 to December 2015. We also searched the National Institute for Health and Care Excellence and the
Scottish Intercollegiate Guidelines Network.
Box 1: What are the symptoms?
• Reduced level of consciousness
• Inability to focus and maintain attention
• Confusion and disorientation
• Daytime somnolence and restlessness at night
• Illusions and hallucinations
• Shifts from hypoactivity to hyperactivity
• Increased or decreased flow of speech
• Increased reaction time
• Enhanced startle reaction
Box 2: Recognised causes of delirium5
• Metabolic disturbance:
– Hypercalcaemia
– Hyponatraemia
– Hypernatraemia
– Dehydration
– Hypoglycaemia or hyperglycaemia
• Organ failure
• Drugs: benzodiazepines, corticosteroids, anticholinergics, opioids, and other drugs with psychoactive properties
• Sepsis
• Brain pathology:
– Primary tumour or metastases
– Cerebrovascular ischaemia
– Status epilepticus
• Hypoxia
• Drug withdrawal states
• Haematological causes:
– Disseminated intravascular coagulation
– Anaemia
Validated tools exist for the screening and diagnosis of delirium
(box 3) and can be used by non-specialists as a first step towards
diagnosis. It is often not practical to use these tools in severe
cases, where cooperation and communication are limited, and
they often lack sufficient sensitivity and specificity to be solely
relied on. Clinicians often use a global clinical assessment based
on detailed history taking, information from care givers, and
pattern recognition7 to make the diagnosis. If the diagnosis is
in doubt, colleagues from palliative medicine or psychiatry can
provide support.
What investigations are required in
palliative care?
Delirium is often a progressive, irreversible process in the last
stages of life. However, some causes, particularly drugs, may
be reversible and probably account for 30-50% of cases.1 13
Decisions on whether to investigate should consider the likely
nature of the underlying cause, the stage of the illness, and the
goals of care pre-established with the patient (box 4).7
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Box 3: Delirium screening and rating tools
Screening tools
• Confusion Assessment Method (CAM)15*: four item diagnostic algorithm used after an assessment of cognition. Requires some training
• Nursing Delirium Rating Scale (Nu-DESC)16†: four item scale that can detect both hypoactive and hyperactive subtypes. Designed
for continuous screening, symptom monitoring, and severity rating
• Single Question in Delirium (SQiD)17†: one question asked of a relative or friend—do you think the patient has been more confused
recently?
Severity assessment tools
• Memorial Delirium Assessment Scale (MDAS)18*: 10 item clinician rated scale for delirium severity assessment
• Delirium Rating Scale-Revised (DRS-R-98)19†: detailed 16 item clinician rated tool that can rate severity and track change over time
*Validated in palliative care settings.20
†Potentially useful, but validity in palliative care lacking.20
Box 4: When and how to investigate
• Consider the stage in the dying process and any agreed goals of care
• Review prescriptions for culpable drugs and the possibility of a withdrawal reaction
• Consider the possibility of alcohol or other substance withdrawal
• Use collateral history to determine rapidity of onset and baseline cognitive function
• If consistent with the goals of care, investigate for other underlying causes and treat where appropriate. Tests include:
• Investigations for metabolic and haematological abnormalities
• Blood cultures
• Midstream specimen of urine
• Chest radiography
• Lumbar puncture
• Electroencephalography
• Computed tomography or magnetic resonance imaging
How is delirium managed in palliative
care?
There is robust evidence that multicomponent delirium
prevention interventions, such as educating nursing staff,
assessing and changing drugs, encouraging mobilisation, and
improving the patient’s environment, can reduce the incidence
of delirium by about 30% in high risk medical and surgical
inpatients,21 but evidence to support this approach in palliative
care is lacking.22 Management of delirium in palliative care
differs little from other settings in broad terms. The focus is on
providing a safe optimised environment (box 5), treating
reversible causes, controlling symptomswith drug and non-drug
interventions, and communicating with patients and family
members.
Treating reversible causes
Review drugs andmodify those that cause or potentiate delirium
(see box 2).
Overall, only about half of delirium episodes are potentially
reversible, although the odds of reversibility are higher when
opioids and other psychoactive drugs are precipitants.1Because
there are often several precipitants or predisposing factors, they
all need to be dealt with simultaneously to reverse up to 50%
of delirium episodes.1
If there are concerns about neurotoxicity in patients taking
opioids, consider a dose reduction or opioid switch. One
observational study of 190 patients treated with opioids showed
that 29 of 42 patients who developed confusion and 10 of 15
who developed hallucinations improved on opioid switching.23
A critical review in 2006 of opioid switching to reduce delirium
suggested overall benefit, although the exact benefit was hard
to define.24
A recent review of parenteral nutrition and hydration at the end
of life suggested that delirium was the only aspect of terminal
symptom control that was likely to benefit from hydration.25 If
an infective cause is suspected, a trial of antibiotics may improve
symptoms of delirium.
Symptom control
Medical strategies for delirium focus on reducing agitation and
perceptual abnormalities.
Although there are several relevant clinical practice
guidelines,10-28 a Cochrane review in 201222 could not make any
drug recommendations in end of life care because of the paucity
of evidence. End of life care was specifically excluded from the
National Institute for Health and Care Excellence (NICE)
guidance on delirium,10 leaving clinicians without pragmatic
guidance although, in practice, clinical management is broadly
similar.
NICE guidance on delirium recommends considering short term
haloperidol or olanzapine in people with delirium who are
distressed or considered a risk to themselves or others and in
whom verbal and non-verbal de-escalation techniques are
ineffective or inappropriate.10 Although this guidance was not
aimed at palliative care, it can help determine when
antipsychotics are appropriate in delirium in palliative care.
Haloperidol remains the drug of choice in delirium, despite
limited evidence of efficacy from randomised controlled trials
(RCTs).29 Like other antipsychotics, it is associated with
extrapyramidal side effects in people over 70 years.30 It is less
sedating than atypical antipsychotics such as risperidone or
olanzapine and is useful where less sedation is required, such
as in hypoactive states. A small RCT in 30 patients with AIDS
related delirium compared haloperidol, chlorpromazine, and
lorazepam.31 Patients in the haloperidol and chlorpromazine
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Box 5: How to optimise the environment for patients with delirium
Promotion of the normal sleep wake cycle
• Ensure lighting levels mimic those that naturally occur for the time of day
• Reduce levels of noise and stimulation at night
Safety
• Undertake a risk assessment of whether the patient is a risk to him/herself or others
• Use 1:1 nursing if necessary
• Use pressure pad alarms—floor mats fitted with pressure alarms that alert the nurses if a patient wanders out of the room or away
from bed
• Remove hazardous objects, such as high beds, electrical cords, knives, and cigarette lighters
Re-orientation
• Clearly display a clock and provide other visual clues to the day and date, such as a daily schedule or newspapers
• Ensure patients have access to their glasses, hearing aids, and interpreters if necessary
• Keep communication clear and consistent
• Identify members of staff to be a point of contact to promote a familiar environment and establish continuity
• Encourage family members to visit and help orient the patient
groups showed improvement in the delirium rating scale (DRS),
whereas those who received lorazepam did not. Those taking
lorazepam had greater side effects than those in the
chlorpromazine and haloperidol groups. In an uncontrolled
observational study of the harms and benefits of haloperidol in
palliative care (119 inpatients and outpatients over 10 days),
12% of patients experienced side effects, most commonly
somnolence or urinary retention.32
A recent RCT in 239 delirious palliative care patients (published
abstract only) compared placebo, haloperidol, and risperidone
over four days.33 Provisional results suggest patients prescribed
haloperidol or risperidone had greater specific delirium
symptoms (communication, behaviour, and perceptual
disturbance) at study end than those prescribed placebo and also
required more midazolam rescue doses.
The low doses of antipsychotics used for delirium are less likely
to be associated with extrapyramidal side effects, but avoid
combinations of antipsychotics and other dopamine blocking
agents such as metoclopramide. Medium to longer term use of
antipsychotics is also associated with increased risk of stroke,34
but these drugs are likely to be used short term in end of life
care.
Despite NICE recommending antipsychotic options for
delirium,10 benzodiazepines are preferred when Lewy body
dementia or Parkinson’s disease coexist because they do not
exacerbate extrapyramidal symptoms. Patients with severe
agitation (anxious, restless, and aggressive behaviour) may also
require a short acting benzodiazepine, such as lorazepam or
midazolam. This can be combined with haloperidol.
Management of refractory delirium
A recent systematic review suggested that refractory delirium
is the most common reason for palliative sedation at the end of
life.35 Palliative sedation is the monitored use of drugs to reduce
awareness in dying patients and relieve suffering from refractory
symptoms. The same systematic review found no evidence that
the use of such proportionate sedation shortened life, although
this finding was based on non-randomised samples.
Palliative sedationmay be appropriate for patients with advanced
disease at the end of life when the cause of delirium is judged
to be irreversible; the manifestations of delirium, such as
frightening cognitions and hallucinations, overwhelm the patient;
or the patient’s behaviour is a threat to him/herself or others.
The aim is to control distress during the dying process. Sedation
is a consequence rather than the objective of treatment. Sedating
antipsychotics such as levomepromazine (methotrimeprazine)
are titrated alone or together with a benzodiazepine such as
midazolam. These are usually given as a subcutaneous infusion
but can be given as regular injections during a titration period
or when infusion devices are unavailable. In rare cases where
these combinations do not control distress, phenobarbitone
injections or infusions can be used, although these
recommendations are not based on evidence from clinical trials
and would require specialist palliative medicine expertise.
Helping families understand delirium
Delirium can be distressing for families.36 The hypoactive form
is often missed by clinicians, and family members may be better
placed to report the subtle changes in presentation that may
herald its onset. A detailed observational study of the experience
of delirium in inpatients with cancer found that mean scores for
distress were higher in the spouses and family care givers who
had witnessed the delirium than in affected patients.37
Furthermore, a qualitative study of 37 family care givers found
that many thought that analgesics caused the delirium.36 The
same study found that distress was lowest in care givers who
were educated about the risk of delirium before it occurred.
Discuss delirium, the likely causes, and what it means for the
patient with family care givers (box 6). Where poor prognostic
factors are identified, discuss this with families so they are aware
that their relative may be entering the last few days of life and
that sedation may be needed for distressing or refractory
symptoms.
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Box 6: Communication with families and friends
• Explain that the patient’s concentration and memory are impaired, and that delirium probably reflects how frail the patient has become
as a result of the illness and infection or the effect of drugs
• Suggest that limited investigations (such as blood tests) and a drugs reviewmight help to diagnose and reverse the delirium if consistent
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• How effective or otherwise are non-pharmacological strategies?
• What are the most effective strategies for supporting families of those affected by delirium?
Further sources of information for patients and professionals
Apps
• Confusion: Delirium and Dementia Application. Available free from iTunes and Google Play. Funded by Health Education England.
Guidance on assessing and managing patients across settings aimed at doctors in training. It includes interactive, validated assessment
scales and management advice
• Delirium Learning Application. Available free from iTunes and Google Play. Developed by NHS Education for Scotland. Provides
accessible advice on the assessment and immediate management of delirium
• Vancouver Island Healthcare (http://www.viha.ca/mhas/resources/delirium/tools.htm). Provides links to rating scales and information
resources that can aid assessment and be used to educate patients
• European Delirium Association (http://www.europeandeliriumassociation.com).http://www.europeandeliriumassociation.com)./ Provides
delirium information resources for health professionals and patients
• National Institute for Health and Care Excellence. (http://www.nice.org.uk/guidance/CG103/ifp/chapter/More-information). Provides
general information for those directly affected by delirium and their carers. It is not aimed at those at the end of life, but most of the
information is highly relevant
• Royal College of Psychiatrists (http://www.rcpsych.ac.uk/expertadvice/problems/physicalillness/delirium.aspx). Provides a brief and
accessible information resource aimed at patients and carers
How patients were involved in the creation of this article
No patients were directly involved in the creation of this article
4 Fang C-K, Chen H-W, Liu S-I, Lin CJ, Tsai LY, Lai YL. Prevalence, detection and treatment
of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol
2008;38:56-63. doi:10.1093/jjco/hym155 pmid:18238881.
5 LeGrand SB. Delirium in palliative medicine: a review. J Pain Symptom Manage
2012;44:583-94. doi:10.1016/j.jpainsymman.2011.10.013 pmid:22682074.
6 Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons.
Predictive model and interrelationship with baseline vulnerability. JAMA 1996;275:852-7.
doi:10.1001/jama.1996.03530350034031 pmid:8596223.
7 Bush SH, Leonard MM, Agar M, et al. End-of-life delirium: issues regarding recognition,
optimal management, and the role of sedation in the dying phase. J Pain SymptomManage
2014;48:215-30. doi:10.1016/j.jpainsymman.2014.05.009 pmid:24879997.
8 Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Underlying pathologies and their
associations with clinical features in terminal delirium of cancer patients. J Pain Symptom
Manage 2001;22:997-1006. doi:10.1016/S0885-3924(01)00360-8 pmid:11738162.
9 Hosie A, Davidson PM, Agar M, Sanderson CR, Phillips J. Delirium prevalence, incidence,
and implications for screening in specialist palliative care inpatient settings: a systematic
review. Palliat Med 2013;27:486-98. doi:10.1177/0269216312457214 pmid:22988044.
10 National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and
management. NICE guideline 103. 2010. https://www.nice.org.uk/guidance/CG103?
UNLID=71857637201581742332.
11 Kurita GP, Sjøgren P, Ekholm O, et al. Prevalence and predictors of cognitive dysfunction
in opioid-treated patients with cancer: a multinational study. J Clin Oncol 2011;29:1297-303.
doi:10.1200/JCO.2010.32.6884 pmid:21357785.
12 Cobb JL, Glantz MJ, Nicholas PK, et al. Delirium in patients with cancer at the end of life.
Cancer Pract 2000;8:172-7. doi:10.1046/j.1523-5394.2000.84006.x pmid:11898256.
13 Leonard M, Raju B, Conroy M, et al. Reversibility of delirium in terminally ill patients and
predictors of mortality. Palliat Med 2008;22:848-54. doi:10.1177/0269216308094520 pmid:
18755829.
14 Bush SH, Kanji S, Pereira JL, et al. Treating an established episode of delirium in palliative
care: expert opinion and review of the current evidence base with recommendations for
future development. J Pain SymptomManage 2014;48:231-48. doi:10.1016/j.jpainsymman.
2013.07.018 pmid:24480529.
15 Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion:
the confusion assessment method. A new method for detection of delirium. Ann Intern
Med 1990;113:941-8. doi:10.7326/0003-4819-113-12-941 pmid:2240918.
16 Gaudreau JD, Gagnon P, Harel F, Tremblay A, Roy MA. Fast, systematic, and continuous
delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain
Symptom Manage 2005;29:368-75. doi:10.1016/j.jpainsymman.2004.07.009 pmid:
15857740.
17 Sands MB, Dantoc BP, Hartshorn A, Ryan CJ, Lujic S. A single question in delirium
(SQiD): testing its efficacy against psychiatrist interview, the confusion assessment method
and the memorial delirium assessment scale. Palliat Med 2010;24:561-5. doi:10.1177/
0269216310371556 pmid:20837733.
18 Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The memorial delirium
assessment scale. J Pain Symptom Manage 1997;13:128-37. doi:10.1016/S0885-3924(
96)00316-8 pmid:9114631.
19 Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium
Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test
for delirium. J Neuropsychiatry Clin Neurosci 2001;13:229-42. doi:10.1176/jnp.13.2.
229 pmid:11449030.
20 Leonard MM, Nekolaichuk C, Meagher DJ, et al. Practical assessment of delirium in
palliative care. J Pain Symptom Manage 2014;48:176-90. doi:10.1016/j.jpainsymman.
2013.10.024 pmid:24766745.
21 Siddiqi N, Harrison JK, Clegg A, et al. Interventions for preventing delirium in hospitalised
non-ICU patients. Cochrane Database Syst Rev 2016;3:CD005563.pmid:26967259.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;353:i3085 doi: 10.1136/bmj.i3085 Page 5 of 6
PRACTICE
22 Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug therapy for delirium
in terminally ill adult patients. Cochrane Database Syst Rev 2012;11:CD004770.pmid:
23152226.
23 de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal
cancer patients. J Pain Symptom Manage 1995;10:378-84. doi:10.1016/0885-3924(95)
90924-C pmid:7673770.
24 Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat
Rev 2006;32:304-15. doi:10.1016/j.ctrv.2006.03.001 pmid:16624490.
25 Dev R, Dalal S, Bruera E. Is there a role for parenteral nutrition or hydration at the end
of life?Curr Opin Support Palliat Care 2012;6:365-70. doi:10.1097/SPC.
0b013e328356ab4a pmid:22801468.
26 National Cancer Institute. Delirium (PDQ)—health professional version. 2015. http://www.
cancer.gov/about-cancer/treatment/side-effects/memory/delirium-hp-pdq.
27 Scotland NHS. Palliative care guidelines: delirium. 2014. http://www.
palliativecareguidelines.scot.nhs.uk/guidelines/symptom-control/Delirium.aspx.
28 Canadian Coalition for Seniors’ Mental Health. Guideline on the assessment and treatment
of delirium in older adults at the end of life. 2010. http://www.ccsmh.ca/en/projects/delirium.
cfm.
29 Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic
review. J Clin Psychiatry 2007;68:11-21. doi:10.4088/JCP.v68n0102 pmid:17284125.
30 Inouye SK, Marcantonio ER, Metzger ED. Doing damage in delirium: the hazards of
antipsychotic treatment in elderly people. Lancet Psychiatry 2014;1:312-5. doi:10.1016/
S2215-0366(14)70263-9 pmid:25285270.
31 Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine,
and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry
1996;153:231-7. doi:10.1176/ajp.153.2.231 pmid:8561204.
32 Crawford GB, Agar M M, Quinn SJ, et al. Pharmacovigilance in hospice/palliative care:
net effect of haloperidol for delirium. J Palliat Med 2013;16:1335-41. doi:10.1089/jpm.
2013.0230 pmid:24138282.
33 Agar M, Lawlor PG, Quinn SJ. Phase lll randomized double-blind controlled trial of oral
risperidone, haloperidol, or placebo with rescue subcutaneous midazolam for delirium
management in palliative care. 2015 Annual American Geriatrics Society Meeting in
Washington DC, USA, May 15th-17th 2015. J Am Geriatr Soc 2015;63(suppl 1):S99.
34 Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case
series study. BMJ 2008;337:a1227. doi:10.1136/bmj.a1227 pmid:18755769.
35 Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a
systematic review. J Clin Oncol 2012;30:1378-83. doi:10.1200/JCO.2011.37.3795 pmid:
22412129.
36 Cohen MZ, Pace EA, Kaur G, Bruera E. Delirium in advanced cancer leading to distress
in patients and family caregivers. J Palliat Care 2009;25:164-71.pmid:19824277.
37 Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and
delirium-related distress in hospitalized patients with cancer, their spouses/caregivers,
and their nurses. Psychosomatics 2002;43:183-94. doi:10.1176/appi.psy.43.3.183 pmid:
12075033.
38 Lawlor PG, Davis DH, Ansari M, et al. An analytical framework for delirium research in
palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge
user perspectives. J Pain SymptomManage 2014;48:159-75. doi:10.1016/j.jpainsymman.
2013.12.245 pmid:24726762.
Published by the BMJ Publishing Group Limited. For permission to use (where not already
granted under a licence) please go to http://group.bmj.com/group/rights-licensing/
permissions
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;353:i3085 doi: 10.1136/bmj.i3085 Page 6 of 6
PRACTICE
